Clinical Trial Update: An Open Label Extension Study of STX209 in Subjects With Fragile X Syndrome [Phase 2]

View source ↗

Summary

Open-label extension study of STX209 (arbaclofen) in Fragile X syndrome in Phase 2 has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fragile Syndrome

Drugs mentioned

• STX209 (arbaclofen)

Snippet

Sponsor: Seaside Therapeutics, Inc. | Conditions: Fragile X Syndrome | Phase 2 | Status: TERMINATED